Bird & Bird represented ArchiMed, a European healthcare-focused private equity fund, in three simultaneous acquisitions that will create an innovative market leader in the bioanalytical market:
- The acquisition of ImaBiotech, a French-based provider specializing in molecular imaging services and products aiming at enhancing the development of new drugs through innovative proprietary technologies,
- The acquisition of Pyxant Labs, a Colorado Springs research lab that specializes in biological testing for the pharmaceutical industry,
- As part of the deal with ArchiMed, Pyxant acquired a Salt Lake City-based bioanalytical and oligonucleotide studies business, creating the US largest independent specialty lab operation focused on testing samples from clinical trial subjects to ensure the safety and effectiveness of new drugs under development.
The Bird & Bird deal team was led by Paris partners Emmanuelle Porte and Bertrand Lévy and associates Olivier Peronnau and Renan Lombard-Platet. Special assistance was provided by partners Benjamin Lichtle (tax) and Anne-Charlotte Le Bihan (IP), and theirs associates Adeline Planckaert and Bertrand Joussain, partners Alexandre Vuchot (commercial) and Nathalie Devernay (labor) and their associates Eric Wallenbrock and Louise Pécard.
